Analyst Tejas Savant from Morgan Stanley maintained a Hold rating on Charles River Labs (CRL – Research Report) and decreased the price target to $184.00 from $220.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tejas Savant’s rating is based on a combination of factors, primarily focusing on the updated financial forecasts and the valuation model applied. The preliminary guidance for 2025 provided by Charles River Labs has led to a revision in the revenue forecasts, which have been lowered for both 2025 and 2026, indicating potential challenges in achieving previous growth expectations.
Savant employed a discounted cash flow analysis with a weighted average cost of capital of 7.5% and a terminal growth rate of 2.0% to determine the price target of $184. This valuation, coupled with the current market conditions and updated revenue outlook, supports a Hold rating as it suggests the stock is fairly valued at its current market price of $161.62.
In another report released yesterday, Evercore ISI also maintained a Hold rating on the stock with a $195.00 price target.